Boston University Researchers Identify Modest Clinician Response to Elevated Lipoprotein(a) Levels in Primary Prevention Patients

Boston University study finds 80% of patients with high Lp(a) do not start new heart medications. Learn why this genetic risk factor remains undertreated.

By: AXL Media

Published: Mar 16, 2026, 12:08 PM EDT

Source: Information for this report was sourced from Boston University School of Medicine

The Clinical Gap in Managing Genetic Cardiovascular Risk

Elevated Lipoprotein(a), commonly referred to as Lp(a), has long been recognized as a significant and genetically determined risk factor for atherosclerotic cardiovascular disease. Despite affecting up to 30% of the global population, a new study from the Boston University Chobanian & Avedisian School of Medicine indicates a lack of systematic clinical response to high concentrations of this lipid. Researchers found that in low-risk populations, clinicians only occasionally adjusted their prescribing behavior in response to elevated levels. This modest response rate highlights a major gap between the identification of a prognostic risk factor and the implementation of aggressive preventive pharmacotherapy in a primary care setting.

Lp(a) as a Risk Enhancer Versus a Treatment Target

According to corresponding author Dr. Sheilah A. Bernard, the medical community currently views elevated Lp(a) as a "risk enhancer" rather than a direct target for therapy. This distinction is critical because, unlike "bad" LDL cholesterol, there are currently no therapies approved specifically and solely for the reduction of Lp(a). Consequently, when a patient presents with a concentration above 50 mg/dL, many clinicians are hesitant to initiate statins or other lipid-lowering drugs in the absence of other traditional risk factors. This selective approach results in a landscape where management is often unstandardized and varies significantly between providers.

Statistical Realities of Preventive Pharmacotherapy Initiation

The retrospective observational cohort study, which evaluated nearly 15,000 patients, provided specific data on how slowly the clinical needle moves following a high Lp(a) reading. Within 90 days of measurement, nearly 80% of those with elevated levels did not start any new lipid-lowering therapy if they were otherwise considered low-risk. While initiation of preventive drugs was technically more frequent among those with high Lp(a) than those without, the overall numbers remained strikingly low. This suggests that while the data is being collected, it is not yet triggering the widespread changes in medication regimes that some cardiovascular experts might expect.